Stockscreener 앱 받기
2.26
1.74%
-0.04
시간 외 거래:
2.28
0.02
+0.88%
전일 마감가:
$2.30
열려 있는:
$2.25
하루 거래량:
966.30K
Relative Volume:
0.78
시가총액:
$257.98M
수익:
$618.00K
순이익/손실:
$-111.65M
주가수익비율:
-1.6189
EPS:
-1.396
순현금흐름:
$-107.53M
1주 성능:
-3.42%
1개월 성능:
-23.65%
6개월 성능:
-52.02%
1년 성능:
-24.92%
1일 변동 폭
$2.22
$2.335
1주일 범위
$2.15
$2.37
52주 변동 폭
$1.955
$6.16
Perspective Therapeutics Inc Stock (CATX) Company Profile
명칭
Perspective Therapeutics Inc
전화
509-375-1202
주소
350 Hills Street, Suite 106, Richland
Compare CATX vs ABT, MDT, SYK, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CATX
Perspective Therapeutics Inc
|
2.26 | 257.98M | 618.00K | -111.65M | -107.53M | -1.396 |
ABT
Abbott Laboratories
|
102.51 | 177.38B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
96.59 | 123.55B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
307.08 | 117.79B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
46.01 | 66.68B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
90.09 | 51.93B | 6.30B | 1.07B | 1.09B | 1.8406 |
Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-09-18 | 개시 | William Blair | Outperform |
| 2026-08-19 | 개시 | BMO Capital Markets | Outperform |
| 2026-02-19 | 개시 | Piper Sandler | Overweight |
| 2025-11-24 | 재개 | Truist | Buy |
| 2025-10-10 | 개시 | BTIG Research | Buy |
| 2025-03-13 | 개시 | H.C. Wainwright | Buy |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2024-11-25 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-10-01 | 개시 | Wedbush | Outperform |
| 2024-09-25 | 개시 | Truist | Buy |
| 2024-07-25 | 개시 | BofA Securities | Buy |
| 2024-05-09 | 개시 | Cantor Fitzgerald | Overweight |
모두보기
Perspective Therapeutics Inc 주식(CATX)의 최신 뉴스
Perspective Therapeutics (CATX) Gets a Hold from Bank of America Securities - The Globe and Mail
Perspective Therapeutics, Inc. (AAJ0.F) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Perspective Therapeutics, Inc. (AAJ0.F) Analyst insights, Price targets and Recommendations - Yahoo Finance Australia
Perspective Therapeutics, Inc. (AAJ0.F) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Perspective Therapeutics (CATX) Receives a Buy from Wedbush - The Globe and Mail
Truist Financial Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Announces Target Price $11 - Moomoo
Strength Seen in Profound Medical (PROF): Can Its 21.7% Jump Turn into More Strength? - Zacks Investment Research
With treatment options limited, a tumor therapy gets FDA Fast Track at Perspective Therapeutics (CATX). - Stock Titan
Perspective Therapeutics Granted Fast Track Designation for - GlobeNewswire
Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous Tumors - Yahoo Finance
Perspective Therapeutics, Inc. (AAJ0.F) stock price, news, quote and history - Yahoo Finance UK
Perspective Therapeutics Announces NANETS 2026 Presentation of [212Pb]VMT-α-NET Clinical Data in Advanced Neuroendocrine Tumors - Quiver Quantitative
Cancer-treatment data will get an oral presentation at a November medical symposium. - Stock Titan
Perspective Therapeutics Announces Acceptance of [212Pb]VMT-α-NET Data for Presentation at the NANETS 2026 Multidisciplinary NET Medical Symposium - GlobeNewswire
UBS Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Perspective Therapeutics, Inc. (CATX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Perspective Therapeutics’ [212Pb]VMT01 Melanoma Data Accepted for Presentation at 2026 SITC Annual Meeting - Quiver Quantitative
A study of a targeted melanoma treatment will be presented at a cancer meeting in November. - Stock Titan
Perspective Therapeutics (CATX) Short Interest & Short Float | Updated Oct 2026 - marketbeat.com
Perspective Therapeutics Announces Acceptance of [212Pb]VMT01 Data for Presentation at SITC 2026 - GlobeNewswire
Form 8K Perspective Therapeutics Inc For: 1 October By Investing.com - Investing.com Nigeria
Three cancer programs are in trials. Perspective Therapeutics (CATX) reports early melanoma results. - Stock Titan
Form 13D/A Perspective Therapeutics For: 26 September By Investing.com - Investing.com Nigeria
After selling nearly 1.4 million shares in one day, a Perspective Therapeutics (CATX) holder still has a stake. - Stock Titan
Perspective Therapeutics (NYSEAM:CATX)Stock Analysis - Simply Wall Street
Perspective Therapeutics, Inc.(NYSEAM:CATX) dropped from S&P Biotechnology Select Industry Index - marketscreener.com
This $3 Biotech Could Be Worth $11.45, Analyst Says - Benzinga
William Blair Initiates Perspective Therapeutics With Outperform Rating - Yahoo Finance
William Blair initiates Perspective Therapeutics stock with outperform rating - Investing.com
Perspective Therapeutics Announces Clinical Trial Collaboration with Merck to Evaluate PSV359 in Combination with Keytruda in Advanced FAP-α-Positive Solid Tumors - Quiver Quantitative
Merck joins Perspective Therapeutics (NYSE: CATX) to test Keytruda combo in Phase 1/2a cancer trial - Stock Titan
Perspective Therapeutics Enters Cancer Clinical Trial Collaboration With Merck; Shares Up Pre-Bell - Yahoo Finance
Perspective Therapeutics partners with Merck on cancer trial - Investing.com
Merck provides Keytruda at no cost for a cancer trial - Stock Titan
Perspective Therapeutics to present NET therapy trial data - grafa.com
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the 38th EORTC-NCI-AACR Symposium 2026 - Yahoo! Finance Canada
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the 38th EORTC-NCI-AACR Symposium 2026 - Yahoo Finance
Perspective Therapeutics Announces Acceptance of Updated [212Pb]VMT-α-NET Data for Presentation at 2026 ENA Symposium | CATX Stock News - Quiver Quantitative
Cancer-treatment data heads to Barcelona on Nov. 20 - Stock Titan
Perspective Therapeutics (CATX) Insider Sale: 10% Owner Lantheus Alpha Therapy, LLC Sells 247,932 Shares - GuruFocus
Perspective Therapeutics updates corporate presentation highlighting 212Pb pipeline, $45B addressable market - TradingView
Perspective Therapeutics (CATX) highlights 3 cancer drug programs - Stock Titan
Perspective Therapeutics (CATX) holder sells stock near $3.10 - Stock Titan
Lantheus Alpha Therapy Sells 113,914 Perspective Therapeutics (AMEX: CATX) Shares at Up to $3.14 Per Share - Kalkine Media
Lantheus Group Reduces Stake in Perspective Therapeutics (AMEX: CATX) to 10% Amid Activist 13D Filing - Kalkine Media
Lantheus Holdings (NASDAQ: LNTH) 10% Stakeholder Alpha Therapy Sells 42,129 Shares at $3.11 Each - Kalkine Media
Perspective Therapeutics (CATX) Insider Sell: 10% Owner Lantheus Alpha Therapy, LLC Disposes of 42,129 Shares - GuruFocus
Perspective Therapeutics (CATX) backer trims stake but keeps 11.5M shares - Stock Titan
10% owner of Perspective Therapeutics (NYSE: CATX) sells 113,914 shares over two days - Stock Titan
Perspective Therapeutics (CATX) backer Lantheus now owns 10% after share sales - Stock Titan
Perspective Therapeutics Inc (CATX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Perspective Therapeutics Inc 주식 (CATX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Lantheus Alpha Therapy, LLC | 10% Owner |
Sep 03 '26 |
Sale |
3.11 |
80,783 |
250,896 |
11,440,513 |
| Lantheus Alpha Therapy, LLC | 10% Owner |
Sep 02 '26 |
Sale |
3.11 |
42,129 |
131,219 |
11,521,296 |
| Lantheus Holdings, Inc. | 10% Owner |
Sep 01 '26 |
Sale |
3.12 |
35,769 |
111,574 |
11,563,425 |
| Lantheus Alpha Therapy, LLC | 10% Owner |
Sep 01 '26 |
Sale |
3.12 |
35,769 |
111,574 |
11,563,425 |
| Lantheus Alpha Therapy, LLC | 10% Owner |
Aug 31 '26 |
Sale |
3.14 |
78,145 |
245,610 |
11,599,194 |
| Lantheus Holdings, Inc. | 10% Owner |
Aug 31 '26 |
Sale |
3.14 |
78,145 |
245,610 |
11,599,194 |
| Hunt Jonathan Robert | Chief Accounting Officer |
Nov 13 '25 |
Buy |
2.03 |
11,000 |
22,295 |
59,800 |
| Williamson Robert F III | Director |
Nov 12 '25 |
Buy |
2.10 |
9,498 |
19,946 |
9,864 |
6.50%
3.38%
자본화:
|
볼륨(24시간):